Stock ABOT ABBOTT LABORATORIES (PAKISTAN) LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Abbott Laboratories (Pakistan) Limited

Equities

ABOT

PK0025701019

Pharmaceuticals

End-of-day quote Pakistan S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
577.6 PKR +0.50% Intraday chart for Abbott Laboratories (Pakistan) Limited +5.41% +25.51%
Mar. 30 Abbott Laboratories Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Abbott Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 61,780 43,740 73,951 70,244 45,358 45,055
Enterprise Value (EV) 1 56,316 41,364 67,278 61,869 36,814 40,176
P/E ratio 22.9 x 33.6 x 16.3 x 11.8 x 15.1 x 172 x
Yield 3.17% 1.68% 5.3% 5.57% 3.24% -
Capitalization / Revenue 2.08 x 1.45 x 2.1 x 1.65 x 0.92 x 0.81 x
EV / Revenue 1.89 x 1.37 x 1.91 x 1.45 x 0.75 x 0.72 x
EV / EBITDA 11.2 x 12.4 x 10.1 x 6.77 x 5.01 x 10.1 x
EV / FCF 80.5 x -29.7 x 11.9 x 11.7 x 9.7 x -16.3 x
FCF Yield 1.24% -3.36% 8.42% 8.53% 10.3% -6.14%
Price to Book 4.67 x 3.27 x 4.74 x 4.05 x 2.65 x 2.47 x
Nbr of stocks (in thousands) 97,900 97,900 97,900 97,900 97,900 97,900
Reference price 2 631.0 446.8 755.4 717.5 463.3 460.2
Announcement Date 3/29/19 3/27/20 3/31/21 3/17/22 3/29/23 3/30/24
1PKR in Million2PKR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 29,719 30,156 35,283 42,570 49,258 55,475
EBITDA 1 5,019 3,338 6,649 9,135 7,353 3,966
EBIT 1 4,282 2,447 5,666 8,006 6,011 2,468
Operating Margin 14.41% 8.11% 16.06% 18.81% 12.2% 4.45%
Earnings before Tax (EBT) 1 4,344 2,511 6,244 8,410 6,148 2,590
Net income 1 2,694 1,300 4,535 5,967 3,004 261.8
Net margin 9.07% 4.31% 12.85% 14.02% 6.1% 0.47%
EPS 2 27.52 13.28 46.33 60.95 30.69 2.674
Free Cash Flow 1 699.8 -1,392 5,664 5,279 3,796 -2,467
FCF margin 2.35% -4.61% 16.05% 12.4% 7.71% -4.45%
FCF Conversion (EBITDA) 13.94% - 85.18% 57.79% 51.62% -
FCF Conversion (Net income) 25.97% - 124.88% 88.47% 126.35% -
Dividend per Share 2 20.00 7.500 40.00 40.00 15.00 -
Announcement Date 3/29/19 3/27/20 3/31/21 3/17/22 3/29/23 3/30/24
1PKR in Million2PKR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 5,464 2,376 6,673 8,376 8,545 4,878
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 700 -1,392 5,664 5,279 3,796 -2,467
ROE (net income / shareholders' equity) 19.5% 9.77% 31.3% 36.2% 17.4% 1.48%
ROA (Net income/ Total Assets) 13.6% 7.45% 15.5% 18.7% 12% 4.37%
Assets 1 19,870 17,442 29,246 31,889 24,984 5,992
Book Value Per Share 2 135.0 137.0 159.0 177.0 175.0 186.0
Cash Flow per Share 2 58.00 28.20 76.50 8.370 81.40 46.40
Capex 1 2,539 1,868 1,380 2,055 3,585 3,075
Capex / Sales 8.54% 6.19% 3.91% 4.83% 7.28% 5.54%
Announcement Date 3/29/19 3/27/20 3/31/21 3/17/22 3/29/23 3/30/24
1PKR in Million2PKR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
ABBOTT LABORATORIES (PAKISTAN) LIMITED Stock Abbott Laboratories (Pakistan) Limited
+25.51% 203M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ABOT Stock
  4. Financials Abbott Laboratories (Pakistan) Limited